Hospital Pharmacies held the dominant position in the duchenne muscular dystrophy drugs market in 2025, accounting for a 43.88% share. Their leadership is maintained through the clinical complexity of Duchenne muscular dystrophy treatment, where drug access is closely tied to specialist care, diagnosis confirmation, dosing oversight, and hospital-led treatment pathways. In practice, many patients receive therapies through institutions that already manage neuromuscular care, making hospital pharmacies the most reliable channel for coordinated dispensing and physician supervision in the duchenne muscular dystrophy drugs market.

Online Pharmacies are emerging as the fastest-growing channel in the duchenne muscular dystrophy drugs market as families and caregivers increasingly value easier refill management and improved access outside major treatment centers. Growth is being underpinned by the practical need to reduce recurring travel and administrative burden for long-term therapy procurement, especially for patients requiring ongoing medication support. Compared with traditional channels, online pharmacies are gaining momentum because they align more directly with convenience-driven purchasing behavior while fitting the expanding expectation for remote access to specialty medicines.

Treatment Segment Analysis: Molecular Based Therapies (Largest Segment) vs Steroid Based Therapies (Fastest-Growing Segment)

With a 44.52% share in 2025, Molecular Based Therapies represented the largest treatment segment in the duchenne muscular dystrophy drugs market. This leadership reflects the market’s shift toward therapies designed to address underlying disease mechanisms rather than only manage symptoms, which has strengthened their role in treatment decision-making. Their position is reinforced by the high clinical focus on targeted intervention in Duchenne muscular dystrophy, making molecular based approaches central to how the duchenne muscular dystrophy drugs market is evolving in specialized care settings.

Steroid Based Therapies are the fastest-growing treatment segment in the duchenne muscular dystrophy drugs market because they remain deeply embedded in routine disease management and are often more immediately accessible within established treatment practice. Their momentum is underpinned by continued real-world reliance on therapies that physicians are familiar with using across a broad patient base, particularly where symptom control and functional preservation remain immediate priorities. Relative to alternatives, steroid based therapies are seeing wider adoption through practical usability and established integration into ongoing care pathways.